ライフサイエンスコーパス: 2-acetylaminofluorene

1 -/-) mice with 2-acetylaminofluorene and NOH-2-acetylaminofluorene.

2 ide, aflatoxin B1 8,9-epoxide, and N-acetoxy-2-acetylaminofluorene.

3 lnitrosamine followed by a brief exposure to 2-acetylaminofluorene.

4 nvolved in rat liver regeneration induced by 2-acetylaminofluorene (2-AAF) and 70% partial hepatectom

5 n of the arylamine 2-aminofluorene (2-AF) to 2-acetylaminofluorene (2-AAF) by acetyl coenzyme A (AcCo

6 The hepatocarcinogen 2-acetylaminofluorene (2-AAF) efficiently activates rat

7 The hepatocarcinogen 2-acetylaminofluorene (2-AAF) efficiently activates rat

8 Administration of 2-acetylaminofluorene (2-AAF) given before a two-thirds

9 Administration of 2-acetylaminofluorene (2-AAF) given before partial hepat

10 sized DNA to examine the earliest effects of 2-acetylaminofluorene (2-AAF) on the mitotic activation

11 periductal cells after their activation with 2-acetylaminofluorene (2-AAF).

12 HOC can be induced to proliferate using a 2-acetylaminofluorene (2-AAF)/hepatic injury (i.e., CCl4

13 ls is a hallmark of liver regeneration after 2-acetylaminofluorene (2-AAF)/partial hepatectomy (PHx)

14 ing oval cell differentiation during the rat 2-acetylaminofluorene (2AAF) and 2/3 partial hepatectomy

15 rgone partial hepatectomy in the presence of 2-acetylaminofluorene (2AAF) or retrorsine, both of whic

16 model system using the carcinogen, N-acetoxy-2-acetylaminofluorene (AAAF), was used to synthesize a N

17 carcinogens 2-aminofluorene (AF), N:-acetyl-2-acetylaminofluorene (AAF) and 1-nitropyrene (1-NP) in

18 utations at G3 by aromatic amine carcinogens 2-acetylaminofluorene (AAF) and 2-aminofluorene (AF) tha

19 ration of hepatocytes is inhibited, and to N-2-acetylaminofluorene (AAF) hepatocarcinogenesis; and 3)

20 and in an experimental cirrhosis induced by 2-acetylaminofluorene (AAF) with carbon tetrachloride (C

21 he well-studied aromatic amine carcinogen, N-2-acetylaminofluorene (AAF), forms adducts at the C8 pos

22 44 rats fed a diet supplemented with 0.03% N-2-acetylaminofluorene (AAF).

23 lly insert C opposite N-(deoxyguanosin-8-yl)-2-acetylaminofluorene (AAF-dG).

24 r DNA adducts: the N-(2'-deoxyguanosin-8-yl)-2-acetylaminofluorene adduct (dG-C8-AAF) and its deacety

25 inofluorene adduct or the helix-distorting N-2-acetylaminofluorene adduct situated at a specific site

26 Even bulky DNA adducts such as N-2-acetylaminofluorene-adducted guanine, (+)- and (-)-tra

27 ns, we treated XPC mutant (XPC-/-) mice with 2-acetylaminofluorene and NOH-2-acetylaminofluorene.

28 o-6-methyldipyridol[1,2-a:3',2'-d]imidazole, 2-acetylaminofluorene, benzidine, 2-naphthylamine, aflat

29 mutation with the model arylamine derivative 2-acetylaminofluorene but G1 is not.

30 major DNA adducts: N-(2'-deoxyguanosin-8-yl)-2-acetylaminofluorene (dG-AAF) and its deacetylated deri

31 genesis studies of N-(2'-deoxyguanosin-8-yl)-2-acetylaminofluorene (dG-AAF) and N-(2'-deoxyguanosin-8

32 ite-specifically with N-(deoxyguanosin-8-yl)-2-acetylaminofluorene (dG-AAF) and N-(deoxyguanosin-8-yl

33 utagenic potential of N-(deoxyguanosin-8-yl)-2-acetylaminofluorene (dG-AAF) and N-(deoxyguanosin-8-yl

34 y major groove adduct N-(deoxyguanosin-8-yl)-2-acetylaminofluorene (dG-AAF).

35 ene (dG-C8-AF) and N-(2'-deoxyguanosin-8-yl)-2-acetylaminofluorene (dG-C8-AAF) adducts that differ by

36 acts with DNA to form N-(deoxyguanosin-8-yl)-2-acetylaminofluorene (dG-C8-AAF), N-(deoxyguanosin-8-yl

37 (dG-C8-AF), and 3-(deoxyguanosin-N(2)()-yl)-2-acetylaminofluorene (dG-N(2)-AAF) DNA adducts.

38 e bulky polycyclic 3-(deoxyguanosin-N(2)-yl)-2-acetylaminofluorene, displayed robust DNA strand-speci

39 en adduct N-(2'-deoxyguanosin-8-yl)-7-fluoro-2-acetylaminofluorene (FAAF) at G(1), G(2) or G(3) of Na

40 inobiphenyl (FABP), 2-aminofluorene (FAF) or 2-acetylaminofluorene (FAAF), and N is either dA or dT.

41 The carcinogen 2-acetylaminofluorene forms two major DNA adducts: N-(2'

42 The carcinogen 2-acetylaminofluorene is metabolically activated in cell

43 owever, pol kappa shows limited bypass of an 2-acetylaminofluorene lesion and can incorporate dCTP or

44 -AG, and 1,3-GTG cisplatin-crosslinks, and a 2-acetylaminofluorene lesion.

45 inogenic hydroxyarylamines such as N-hydroxy-2-acetylaminofluorene (N-OH-2AAF) can be further activat

46 ng cultured human cells exposed to N-acetoxy-2-acetylaminofluorene (NA-AAF), which generates bulky DN

47 containing bulky adducts formed by N-acetoxy-2-acetylaminofluorene or benzo(a)pyrene diol epoxide.

48 orting base adduct N-(2'-deoxyguanosin-8-yl)-2-acetylaminofluorene over non-damaged dsDNA.

49 institution in rats of a diethylnitrosamine, 2-acetylaminofluorene, partial hepatectomy carcinogenesi

50 cell-mediated liver regeneration induced by 2-acetylaminofluorene/partial hepatectomy (AAF/PH) proto

51 During the hepatic stem cell activation (2-acetylaminofluorene/partial hepatectomy [AAF/PH] model

52 Four weeks later, rats were subjected to the 2-acetylaminofluorene/partial hepatectomy model of oval

53 expression was knocked down in the liver of 2-acetylaminofluorene/partial hepatectomy-treated rats u

54 vation during liver regeneration following N-2-acetylaminofluorene/partial hepatectomy.

55 and ST1E2 mRNAs (corresponding to N-hydroxy-2-acetylaminofluorene ST and estrogen ST, respectively)

56 Transplanted rats were treated with 2-acetylaminofluorene, to block hepatocyte proliferation

57 Oval cells were activated in 2-acetylaminofluorene-treated rats subjected to partial

58 ce markers in the liver of rats subjected to 2-acetylaminofluorene treatment followed by partial hepa

59 ing OC activation, after the implantation of 2-acetylaminofluorene with partial hepatectomy in rats o

60 on of miR-133b in DR/OC activation models of 2-acetylaminofluorene with partial hepatectomy in rats,

61 induced in the rat DR/OC activation model of 2-acetylaminofluorene with partial hepatectomy.